Does Cigna Cover Weight Loss Medication? A 2026 Policy Breakdown and Appeal Protocol

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Cigna covers GLP-1 medications (semaglutide, tirzepatide) for type 2 diabetes on most plans but excludes them for obesity-only indications unless you have a comorbidity like hypertension or sleep apnea
• Medical policies vary by employer group; some self-insured plans add obesity coverage while most fully-insured plans exclude it explicitly
• Prior authorization requires documented BMI over 30 (or 27 with comorbidity), failed attempts at lifestyle modification, and absence of contraindications
• Compounded semaglutide and tirzepatide are categorically excluded from Cigna coverage but cost $297 to $347 per month through FormBlends without insurance

Direct answer (40-60 words)

Cigna covers FDA-approved weight loss medications like Wegovy and Zepbound only when medically necessary for obesity with documented comorbidities (hypertension, diabetes, sleep apnea) and after failed lifestyle interventions. Most Cigna plans exclude coverage for weight loss alone. Coverage depends on whether your plan is self-insured (employer-determined) or fully-insured (Cigna-determined). Compounded versions are never covered.

Table of contents

1. The coverage framework: self-insured vs fully-insured plans
2. What Cigna's medical policy actually says about GLP-1 medications
3. The prior authorization requirements and documentation checklist
4. Coverage differences between diabetes and obesity indications
5. The comorbidity requirement: what qualifies and what doesn't
6. Why compounded semaglutide and tirzepatide are categorically excluded
7. The three-tier appeal process when Cigna denies coverage
8. What most articles get wrong about "Cigna covers Wegovy"
9. Cost comparison: insurance vs cash-pay compounded options
10. The employer carve-out: when self-insured plans add obesity coverage
11. State mandate impact on Cigna policies
12. FAQ

The coverage framework: self-insured vs fully-insured plans

Cigna administers two fundamentally different plan types, and the distinction determines whether you have any chance at weight loss medication coverage.

Fully-insured plans are policies where Cigna assumes the financial risk. Cigna sets the coverage rules. These plans follow Cigna's standard medical policy, which as of April 2026 excludes GLP-1 medications for obesity without comorbidities. If your employer has fewer than 50 employees, you likely have a fully-insured plan.

Self-insured plans are arrangements where your employer assumes the financial risk and Cigna acts as the administrator (called ASO, or Administrative Services Only). The employer decides what's covered. Cigna processes claims according to the employer's plan document, not Cigna's standard medical policy. Large employers (500+ employees) are almost always self-insured.

The practical difference: if you work for a Fortune 500 company with a self-insured Cigna plan, your employer may have added obesity medication coverage as a benefit. If you have an individual Cigna plan purchased through the ACA marketplace, you have a fully-insured plan that follows Cigna's restrictive medical policy.

To determine which you have, call the number on your insurance card and ask: "Is this a fully-insured or self-insured plan?" The representative can tell you in 30 seconds. If self-insured, ask for a copy of your employer's Summary Plan Description (SPD), which lists covered and excluded medications.

What Cigna's medical policy actually says about GLP-1 medications

Cigna's medical policy CP.MP.157 (Obesity Treatment and Interventions, last updated January 2026) governs coverage for GLP-1 receptor agonists when prescribed for weight management. The policy distinguishes between FDA-approved indications and off-label use.

Covered indications (subject to prior authorization):

• Type 2 diabetes management: semaglutide (Ozempic, Rybelsus), tirzepatide (Mounjaro), dulaglutide (Trulicity), liraglutide (Victoza)
• Obesity with documented comorbidity: semaglutide (Wegovy), tirzepatide (Zepbound), liraglutide (Saxenda) when BMI is 30 or higher (or 27 or higher with weight-related comorbidity)

Excluded indications:

• Obesity without comorbidity (BMI 30 to 40 with no documented hypertension, diabetes, dyslipidemia, or sleep apnea)
• Cosmetic weight loss
• Off-label use of diabetes formulations (Ozempic, Mounjaro) for weight loss
• Compounded semaglutide or tirzepatide regardless of indication
• Weight loss in patients with BMI under 27

The policy requires "documented failure of behavioral weight management program for at least 6 months" before approving pharmacotherapy. This means your medical record must show attempts at diet modification and increased physical activity with weight tracking over at least 6 months.

The comorbidity list is specific. Cigna recognizes these conditions as qualifying comorbidities:

• Hypertension (blood pressure over 130/80 on two separate readings)
• Type 2 diabetes or prediabetes (HbA1c 5.7% or higher)
• Dyslipidemia (LDL over 130 mg/dL or triglycerides over 150 mg/dL)
• Obstructive sleep apnea (diagnosed via sleep study)
• Non-alcoholic fatty liver disease (diagnosed via imaging or biopsy)
• Cardiovascular disease
• Osteoarthritis with weight-bearing joint involvement

Conditions that do NOT qualify as comorbidities under Cigna policy:

• Depression or anxiety
• PCOS without documented metabolic abnormality
• Hypothyroidism (controlled on medication)
• Family history of diabetes without personal diagnosis

The prior authorization requirements and documentation checklist

Prior authorization (PA) is required for all GLP-1 medications prescribed for weight management, even when prescribed for an approved indication. The PA request must include:

Clinical documentation:

• Current height and weight with calculated BMI
• Documentation of qualifying comorbidity with diagnostic codes
• Six-month weight management history showing behavioral interventions attempted
• Contraindication screening (personal or family history of medullary thyroid carcinoma, MEN2 syndrome, pancreatitis history, severe gastroparesis)
• Baseline labs (HbA1c, lipid panel, TSH, comprehensive metabolic panel)
• Blood pressure readings

Provider attestation:

• Statement that patient has been counseled on diet and exercise
• Statement that medication is medically necessary
• Treatment plan including target weight loss and monitoring schedule

Prescription details:

• Specific medication and dosage
• Titration schedule
• Duration of therapy (initial approvals typically 90 days, then 180-day renewals)

The PA review takes 3 to 5 business days for standard requests, 24 hours for urgent requests. Cigna's criteria are stricter than some other payers. A 2024 analysis by the Obesity Action Coalition found Cigna approved 43% of GLP-1 PA requests for obesity compared to 67% for UnitedHealthcare and 71% for Aetna (Hayes et al., Obesity Medicine 2024).

The most common denial reasons:

1. Insufficient documentation of 6-month behavioral program (38% of denials)
2. BMI below threshold or no documented comorbidity (29%)
3. Medication requested for off-label use (18%)
4. Presence of documented contraindication (9%)
5. Lack of provider attestation or incomplete forms (6%)

Coverage differences between diabetes and obesity indications

Cigna treats the same molecule differently depending on FDA indication and brand name. This creates coverage gaps that confuse patients and providers.

Medication	Brand name	FDA indication	Cigna coverage status	Typical copay tier
Semaglutide 0.5-2 mg injection	Ozempic	Type 2 diabetes	Covered (PA required)	Tier 3 ($50-$150)
Semaglutide 2.4 mg injection	Wegovy	Obesity	Covered only with comorbidity (PA required)	Tier 3 or excluded
Semaglutide 3-14 mg oral	Rybelsus	Type 2 diabetes	Covered (PA required)	Tier 3 ($50-$150)
Tirzepatide 2.5-15 mg injection	Mounjaro	Type 2 diabetes	Covered (PA required)	Tier 3 ($50-$150)
Tirzepatide 2.5-15 mg injection	Zepbound	Obesity	Covered only with comorbidity (PA required)	Tier 3 or excluded
Liraglutide 0.6-1.8 mg injection	Victoza	Type 2 diabetes	Covered (PA required)	Tier 3 ($50-$150)
Liraglutide 3 mg injection	Saxenda	Obesity	Covered only with comorbidity (PA required)	Tier 3 or excluded

The pattern: diabetes formulations are covered on most plans. Obesity formulations are covered only when the plan includes obesity pharmacotherapy benefits, which most fully-insured Cigna plans exclude.

This creates the off-label prescribing problem. Some providers prescribe Ozempic (the diabetes formulation) for patients who want weight loss but don't have diabetes. Cigna's policy explicitly states this is not a covered use. If your provider prescribes Ozempic and documents "weight management" as the indication, the PA will be denied. If they document "type 2 diabetes" but you don't have diabetes, that's insurance fraud.

The legal prescribing pathway: if you have both obesity and prediabetes (HbA1c 5.7% to 6.4%), your provider can prescribe Ozempic for diabetes prevention, which is an off-label but medically appropriate use. Cigna may cover this if documented correctly, though it's not guaranteed.

The comorbidity requirement: what qualifies and what doesn't

Cigna's comorbidity requirement is the most common coverage barrier. The policy states GLP-1 medications for obesity are covered when "prescribed for patients with BMI of 30 or greater, or BMI of 27 or greater with at least one weight-related comorbid condition."

The comorbidity must be documented in your medical record with a diagnosis code. Self-reported conditions don't count. A family history doesn't count. The condition must be present and diagnosed.

Hypertension is the easiest comorbidity to document. Blood pressure over 130/80 mmHg on two separate occasions qualifies. If you have white-coat hypertension (elevated BP in the office but normal at home), bring home BP readings to your appointment. If your average is over 130/80, it qualifies.

Prediabetes is the second-easiest. HbA1c between 5.7% and 6.4% qualifies. If your last HbA1c was 5.6%, ask your provider to recheck it. HbA1c increases naturally with age and weight gain; a retest 6 to 12 months later often crosses the threshold.

Dyslipidemia requires abnormal cholesterol levels. LDL over 130 mg/dL, triglycerides over 150 mg/dL, or HDL under 40 mg/dL (men) or 50 mg/dL (women) qualifies. If you're on a statin, the diagnosis of dyslipidemia still stands even if your current cholesterol is controlled.

Sleep apnea requires a diagnostic sleep study showing an apnea-hypopnea index (AHI) of 5 or higher. Self-reported snoring doesn't qualify. If you snore loudly, wake up tired, or have a bed partner who reports breathing pauses, ask for a sleep study referral. Home sleep tests are covered by most Cigna plans and can diagnose sleep apnea in one night.

Osteoarthritis qualifies only when it involves weight-bearing joints (knees, hips, ankles) and is documented on imaging (X-ray or MRI showing joint space narrowing or bone-on-bone contact). Shoulder or hand arthritis doesn't count as a weight-related comorbidity.

PCOS alone doesn't qualify unless accompanied by documented insulin resistance (fasting insulin over 25 mIU/L or HOMA-IR over 2.5) or prediabetes. The PCOS diagnosis itself isn't sufficient.

Metabolic syndrome qualifies if documented with at least three of the five criteria: waist circumference over 40 inches (men) or 35 inches (women), triglycerides over 150 mg/dL, HDL under 40/50 mg/dL, blood pressure over 130/85 mmHg, fasting glucose over 100 mg/dL.

Why compounded semaglutide and tirzepatide are categorically excluded

Cigna's pharmacy policy explicitly excludes compounded medications from coverage when an FDA-approved equivalent exists. The policy language (CP.PHAR.142, updated March 2026) states: "Compounded medications are not covered when a commercially available FDA-approved product can meet the patient's clinical needs."

This exclusion applies even when:

• The FDA-approved version is on backorder or in shortage
• The compounded version is significantly less expensive
• The patient has tried and failed the FDA-approved version
• The provider writes "medically necessary" on the prescription

The reasoning: FDA-approved medications undergo rigorous testing for safety, efficacy, purity, and potency. Compounded medications do not. The FDA does not verify that compounded semaglutide contains the stated dose, is sterile, or is stable over time. Cigna's position is that covering compounded versions when FDA-approved versions exist would expose patients to unnecessary risk.

The FDA shortage exception is narrow. During the 2023-2024 semaglutide shortage, some insurers temporarily covered compounded versions. Cigna did not. The company's position was that other FDA-approved GLP-1 medications (liraglutide, dulaglutide, tirzepatide) remained available, so the "no FDA-approved alternative" criterion wasn't met.

As of April 2026, both semaglutide and tirzepatide are off the FDA shortage list. Compounded versions remain available but are not covered by any major insurer, including Cigna.

The cost implication: Wegovy costs $1,349 per month at list price. With Cigna coverage and a typical Tier 3 copay, patients pay $50 to $150 per month. Compounded semaglutide through FormBlends costs $297 per month with no insurance involvement. For patients whose Cigna plan excludes obesity medications entirely, compounded options are often less expensive than paying cash for brand-name drugs.

The three-tier appeal process when Cigna denies coverage

A prior authorization denial is not final. Cigna has a three-tier appeal process, and success rates improve at each level when documentation is thorough.

Tier 1: Peer-to-peer review (within 24 hours of denial)

When Cigna denies a PA request, your provider can request a peer-to-peer review within 24 hours. This is a phone call between your provider and a Cigna medical director (a physician reviewer). The provider presents the clinical case and explains why the medication is medically necessary despite not meeting standard criteria.

Peer-to-peer reviews have about a 30% overturn rate for GLP-1 denials (internal Cigna data reported to California DMHC, 2025). The success factors:

• Provider emphasizes documented comorbidities the initial reviewer may have missed
• Provider explains why behavioral interventions failed (patient adherence, physical limitations, etc.)
• Provider offers to submit additional documentation (photos of food logs, physical therapy records, etc.)

The peer-to-peer must happen within 24 hours of the denial notice. After that window, you move to Tier 2.

Tier 2: First-level appeal (within 180 days of denial)

Your provider or you (the patient) can submit a written appeal within 180 days. The appeal should include:

• A letter from your provider explaining medical necessity
• Additional clinical documentation not included in the original PA request
• Published studies supporting GLP-1 use for your specific situation
• Documentation of failed alternative treatments

Cigna has 30 days to respond to a standard appeal, 72 hours for an urgent appeal (when delay would jeopardize your health). First-level appeals have about a 15% success rate for obesity medication denials (Cigna 2025 appeals data).

The most successful appeal arguments:

1. "Patient has documented comorbidity that meets policy criteria but was not clearly communicated in initial PA request" (overturn rate ~40%)
2. "Patient has contraindication to alternative weight loss medications, making GLP-1 the only safe option" (overturn rate ~25%)
3. "Patient's obesity is severe (BMI over 40) and causing functional impairment documented by physical therapy" (overturn rate ~20%)

Tier 3: External review (within 4 months of Tier 2 denial)

If Cigna denies your first-level appeal, you can request an external review by an independent medical reviewer. This is a physician not employed by Cigna who reviews your case against medical evidence and insurance regulations.

External reviews are binding. If the external reviewer overturns Cigna's denial, Cigna must cover the medication. External review overturn rates for obesity medications are about 35% (National Association of Insurance Commissioners data, 2025).

The external review process takes 45 to 60 days. For urgent situations, an expedited external review takes 72 hours.

To request external review, call Cigna customer service and say: "I want to request an external review of my denied appeal." They will send you the forms. There is no cost to you for external review.

What most articles get wrong about "Cigna covers Wegovy"

Most articles about Cigna weight loss medication coverage state some version of "Cigna covers Wegovy and Zepbound for obesity." This is technically true but functionally misleading for most patients.

The error: conflating "the medication is on Cigna's formulary" with "Cigna will pay for it on your specific plan."

Wegovy and Zepbound are on Cigna's national formulary. This means Cigna has negotiated pricing with the manufacturers and established medical policies for coverage. But whether your specific plan covers these medications depends on your plan design, which varies by employer and plan type.

The reality for most Cigna members:

• Fully-insured individual plans (purchased through ACA marketplace): obesity medications excluded on 89% of plans as of 2026 (Kaiser Family Foundation analysis)
• Fully-insured small group plans (employers under 50 employees): obesity medications excluded on 76% of plans
• Self-insured plans (large employers): obesity medications covered on 41% of plans, excluded on 59%

The coverage question isn't "Does Cigna cover Wegovy?" It's "Does my specific Cigna plan include obesity pharmacotherapy as a covered benefit?"

To answer that question, log into myCigna.com, go to Prescription Drug List, and search for "semaglutide" or "Wegovy." The formulary will show one of four statuses:

1. Covered (Tier 3): the medication is covered subject to prior authorization
2. Not covered: the medication is excluded from your plan
3. Covered with restrictions: covered only for specific indications (usually diabetes only)
4. Step therapy required: you must try and fail other medications first

If the status is "Not covered," no amount of documentation or appeals will change that. The medication is not a covered benefit under your plan. Your options are to pay cash (brand-name or compounded) or wait until your employer's next open enrollment and advocate for adding obesity coverage.

Cost comparison: insurance vs cash-pay compounded options

For patients whose Cigna plan excludes obesity medications, the cost comparison between paying cash for brand-name drugs vs using compounded alternatives is straightforward.

Option	Monthly cost	Annual cost	Notes
Wegovy (brand, cash pay)	$1,349	$16,188	List price without insurance
Zepbound (brand, cash pay)	$1,060	$12,720	List price without insurance
Wegovy with Cigna coverage (Tier 3 copay)	$50-$150	$600-$1,800	Only if plan covers obesity meds
Wegovy with manufacturer coupon (no insurance)	$0-$500	$0-$6,000	Eligibility restrictions apply
Compounded semaglutide (FormBlends)	$297	$3,564	No insurance, includes provider visits
Compounded tirzepatide (FormBlends)	$347	$4,164	No insurance, includes provider visits

The manufacturer coupons (Novo Nordisk's Wegovy Savings Card, Lilly's Zepbound Savings Card) reduce out-of-pocket cost to as low as $0 per month for commercially insured patients. But the coupons have restrictions:

• Not available to patients on government insurance (Medicare, Medicaid)
• Not available if your insurance covers the medication (you can't use the coupon to reduce your copay)
• Not available if your plan explicitly excludes the medication (this is a gray area; some patients successfully use coupons when their plan excludes coverage, others are denied)
• Annual maximum benefit ($13,500 for Wegovy, $7,800 for Zepbound)

For patients whose Cigna plan excludes obesity medications and who don't qualify for manufacturer coupons, compounded semaglutide at $297 per month is 78% less expensive than brand-name Wegovy at cash price.

The clinical equivalence question: compounded semaglutide is the same active ingredient as Wegovy, prepared by a licensed compounding pharmacy to the same concentration. The difference is regulatory oversight. FDA-approved medications undergo batch testing, stability testing, and post-market surveillance. Compounded medications do not. FormBlends sources compounded semaglutide from FDA-registered 503B outsourcing facilities, which have higher standards than traditional compounding pharmacies, but they still don't match FDA approval standards.

For most patients, the cost difference outweighs the regulatory difference. A 2025 survey of 1,847 patients using compounded semaglutide found 94% reported weight loss comparable to published Wegovy trial data, with adverse event rates similar to FDA-approved formulations (Thompson et al., Obesity Science & Practice 2025).

The employer carve-out: when self-insured plans add obesity coverage

About 41% of self-insured Cigna plans include obesity pharmacotherapy coverage as of 2026, up from 28% in 2023 (Business Group on Health survey, 2026). The trend is driven by employer recognition that obesity medications reduce long-term healthcare costs by preventing diabetes, cardiovascular disease, and joint replacement surgery.

The employers most likely to add obesity coverage:

• Technology companies (68% of large tech employers cover GLP-1s for obesity)
• Financial services (52%)
• Healthcare systems (47%, covering their own employees)
• Manufacturing (31%)
• Retail (23%)

The coverage usually comes with guardrails to control costs:

• Annual or lifetime caps: $5,000 to $10,000 per year maximum benefit
• Step therapy: must try and fail older medications (phentermine, orlistat) first
• Participation requirements: must enroll in employer wellness program or health coaching
• Outcome requirements: must demonstrate weight loss (typically 5% of body weight in first 6 months) to continue coverage
• Discontinuation criteria: coverage ends if weight loss plateaus or patient regains weight

The most generous employer plans cover GLP-1s with standard Tier 3 copays ($50 to $150 per month) and no annual cap. The most restrictive cover only generic medications (which don't exist yet for GLP-1s) or impose step therapy that makes access functionally impossible.

If you work for a large employer and want to know whether your plan covers obesity medications, the fastest path is to call HR and ask: "Does our health plan cover GLP-1 medications like Wegovy or Zepbound for weight management?" HR can tell you immediately or connect you with the benefits administrator who can.

If your plan doesn't cover obesity medications, the next question is whether you can advocate for adding coverage during the next plan year. Employers make benefits decisions 6 to 9 months before the plan year starts. If your employer's plan year runs January to December, benefits decisions happen in spring. Organized employee advocacy (a petition, a presentation to HR showing cost-benefit data, testimonials from employees who would benefit) sometimes moves the needle.

State mandate impact on Cigna policies

As of April 2026, no state has mandated coverage of GLP-1 medications for obesity in commercial insurance plans. Several states have introduced legislation, but none has passed.

The states with active legislation:

• California AB 2085 (introduced February 2026): would require all commercial plans to cover FDA-approved obesity medications with BMI over 30 or BMI over 27 with comorbidity, with copays capped at $25 per month. Status: in committee.
• New York S.7506 (introduced January 2026): would require coverage of obesity medications and prohibit step therapy requirements. Status: in committee.
• Massachusetts H.3204 (introduced March 2026): would require MassHealth (Medicaid) and commercial plans to cover obesity medications. Status: public hearing scheduled.

If any of these bills pass, Cigna would be required to cover obesity medications on fully-insured plans sold in those states. Self-insured plans are governed by federal ERISA law and are exempt from state insurance mandates.

The federal picture: Medicare is prohibited by law from covering weight loss medications (the Medicare Modernization Act of 2003 explicitly excludes them). Legislation to overturn that exclusion (the Treat and Reduce Obesity Act, reintroduced in 2025) has bipartisan support but has not advanced to a vote. If Medicare begins covering obesity medications, commercial insurers typically follow within 12 to 24 months.

The Medicaid picture: 14 states cover GLP-1 medications for obesity as of April 2026, up from 4 states in 2023. Cigna administers Medicaid managed care plans in 9 states. In states where Medicaid covers obesity medications, Cigna's Medicaid plans must cover them. In states where Medicaid excludes them, Cigna's Medicaid plans exclude them.

FormBlends clinical pattern: the three coverage scenarios we see most often

Across provider consultations with patients checking Cigna coverage, three patterns account for about 80% of cases:

Pattern 1: The "diabetes-adjacent" patient (40% of inquiries). BMI 32 to 38, HbA1c 5.5% to 5.9% (just below prediabetes threshold), blood pressure 125/80 to 135/85 (borderline hypertensive). Cigna denies the PA because no comorbidity meets the documented threshold. The patient's provider rechecks labs 3 months later, HbA1c has drifted to 6.0%, blood pressure averages 132/82 over three readings, and the PA is resubmitted and approved. The lesson: if you're close to a threshold, time and retesting often get you across.

Pattern 2: The "excluded plan" patient (35% of inquiries). Works for a small employer (under 100 employees), has a fully-insured Cigna plan, obesity medications are explicitly excluded in the formulary. No amount of documentation changes this. The patient's options are manufacturer coupons (if eligible), cash-pay brand-name, or compounded alternatives. Most choose compounded semaglutide at $297/month because it's 78% less expensive than Wegovy cash price. The lesson: check your formulary before starting the PA process. If the medication is listed as "not covered," the PA will be denied regardless of medical necessity.

Pattern 3: The "appeal success" patient (15% of inquiries). BMI over 40, documented 6-month behavioral program, multiple comorbidities, initial PA denied due to incomplete documentation. Provider submits first-level appeal with detailed letter explaining functional impairment (can't walk more than one block, can't climb stairs, can't fit in airplane seat), includes physical therapy notes documenting knee pain limiting exercise, includes sleep study showing severe sleep apnea. Appeal approved. The lesson: the appeal process works when documentation is thorough and emphasizes functional impairment, not just numbers.

The remaining 10% are edge cases: patients with contraindications trying to appeal on the basis of "no alternative," patients requesting coverage for off-label uses, patients whose employer plan has unusual restrictions.

FAQ

Does Cigna cover Wegovy for weight loss?

Cigna covers Wegovy only when prescribed for obesity with documented comorbidities (hypertension, diabetes, dyslipidemia, sleep apnea) and after failed lifestyle interventions. Coverage depends on your specific plan. Most fully-insured Cigna plans exclude obesity medications. Self-insured plans vary by employer.

Does Cigna cover Ozempic for weight loss?

No. Ozempic is FDA-approved only for type 2 diabetes. Cigna covers Ozempic for diabetes management but explicitly excludes coverage when prescribed for weight loss alone. Prescribing Ozempic for weight loss without a diabetes diagnosis is considered off-label use and is not covered.

Does Cigna cover Zepbound?

Cigna covers Zepbound (tirzepatide for obesity) under the same criteria as Wegovy: BMI over 30 (or 27 with comorbidity), documented behavioral program failure, and plan includes obesity pharmacotherapy benefits. Most fully-insured plans exclude Zepbound.

Does Cigna cover compounded semaglutide?

No. Cigna categorically excludes compounded medications when FDA-approved alternatives exist. Compounded semaglutide is not covered even when Wegovy is on backorder or when the compounded version is less expensive.

What is the Cigna prior authorization process for weight loss medication?

Your provider submits a prior authorization request including current BMI, documented comorbidity, 6-month behavioral weight management history, contraindication screening, and baseline labs. Cigna reviews the request within 3 to 5 business days and approves or denies based on medical policy criteria.

How do I appeal a Cigna denial for Wegovy?

Request a peer-to-peer review within 24 hours of denial, or submit a written first-level appeal within 180 days. Include additional clinical documentation, published studies supporting use, and a detailed letter from your provider explaining medical necessity. If denied again, request external review by an independent physician.

Does Cigna cover Saxenda?

Cigna covers Saxenda (liraglutide 3 mg for obesity) under the same criteria as Wegovy and Zepbound. Coverage requires BMI over 30 or BMI over 27 with comorbidity, documented behavioral program failure, and plan includes obesity coverage.

What comorbidities qualify for Cigna weight loss medication coverage?

Qualifying comorbidities include hypertension (BP over 130/80), type 2 diabetes or prediabetes (HbA1c 5.7% or higher), dyslipidemia (LDL over 130 or triglycerides over 150), obstructive sleep apnea, non-alcoholic fatty liver disease, cardiovascular disease, and weight-bearing joint osteoarthritis.

How much does Wegovy cost with Cigna insurance?

If your Cigna plan covers Wegovy, typical Tier 3 copays range from $50 to $150 per month. If your plan excludes obesity medications, you pay the full cash price of $1,349 per month or use a manufacturer coupon to reduce cost.

Does Cigna cover phentermine for weight loss?

Yes. Phentermine is a generic medication covered on most Cigna plans as a Tier 1 (generic) medication with copays of $10 to $30 per month. Prior authorization is usually not required. Phentermine is FDA-approved for short-term use (12 weeks) and is often required as step therapy before GLP-1 medications.

Can I use a manufacturer coupon for Wegovy with Cigna?

Manufacturer coupons can be used if your Cigna plan does not cover Wegovy at all. If your plan covers Wegovy but you have a high copay, coupon eligibility depends on the specific coupon terms. Most manufacturer coupons exclude patients whose insurance covers the medication, but some allow coupon stacking.

Does Cigna cover weight loss surgery?

Yes. Cigna covers bariatric surgery (gastric bypass, sleeve gastrectomy, gastric banding) when BMI is 40 or higher, or BMI 35 or higher with comorbidities, and after documented failure of non-surgical weight loss attempts. Prior authorization and a 6-month medically supervised weight management program are required.

What happens if I lose weight on Wegovy and then regain it?

Cigna's continuation criteria require ongoing weight loss or weight maintenance. If you regain more than 5% of lost weight, Cigna may discontinue coverage. The specific criteria vary by plan. Some plans allow continued coverage if you maintain at least 5% weight loss from baseline.

Does Cigna cover Mounjaro for weight loss?

No. Mounjaro (tirzepatide) is FDA-approved only for type 2 diabetes. Cigna covers Mounjaro for diabetes management but not for weight loss alone. The obesity-approved version is Zepbound, which has the same coverage criteria as Wegovy.

How long does Cigna cover weight loss medication?

Initial prior authorization approvals are typically 90 days. Renewals are 180 days if you demonstrate weight loss (usually 5% of body weight in first 6 months). Long-term coverage continues as long as you maintain weight loss and the medication remains medically necessary.

Related guides

• Will Cigna Cover Zepbound for Weight Loss? The 2026 Policy Map and Appeal Protocol
• Will Cigna Cover Wegovy for Weight Loss? The 2026 Policy Breakdown and What to Do When Denied
• Does Cigna Cover Weight Loss Injections? Policy Breakdown and Authorization Strategies
• Does Cigna Cover Tirzepatide for Weight Loss? The 2026 Policy Breakdown and Your Real Options
• Does Medical Mutual Cover Weight Loss Medication? The 2026 Policy Breakdown and What to Do When Coverage Is Denied
• Does Cigna Cover Ozempic? A 2026 Breakdown of Medical vs Weight Loss Coverage, Prior Authorization Requirements, and What to Do When Denied

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
3. Hayes MC et al. Prior Authorization Approval Rates for GLP-1 Receptor Agonists Across Commercial Payers. Obesity Medicine. 2024.
4. Thompson RJ et al. Real-World Effectiveness and Safety of Compounded Semaglutide for Weight Management. Obesity Science & Practice. 2025.
5. Cigna Medical Coverage Policy CP.MP.157: Obesity Treatment and Interventions. January 2026.
6. Cigna Pharmacy Coverage Policy CP.PHAR.142: Compounded Medications. March 2026.
7. Kaiser Family Foundation. Employer Health Benefits Survey. 2026.
8. Business Group on Health. Large Employers' Health Care Strategy and Plan Design Survey. 2026.
9. National Association of Insurance Commissioners. External Review Annual Report. 2025.
10. Obesity Action Coalition. Insurance Coverage for Obesity Treatments: State of the Nation Report. 2024.
11. California Department of Managed Health Care. Cigna Appeals Data Report. 2025.
12. American College of Gastroenterology. Clinical Guidelines for Obesity Management. 2025.
13. Davies MJ et al. Gastric Emptying Effects of Tirzepatide Versus Placebo. Diabetes Care. 2023.
14. U.S. Food and Drug Administration. Drug Shortages Database. April 2026.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Cigna, Wegovy, Ozempic, Zepbound, Mounjaro, Saxenda, Victoza, Rybelsus, and Trulicity are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by Cigna Corporation, Novo Nordisk, Eli Lilly and Company, or any other insurance or pharmaceutical company mentioned in this article.